Quick Answer
Bone Biologics Corp reported Diluted EPS of $2.65 per share (loss) for fiscal year 2025.
Bone Biologics Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.65 | +90.8% |
| 2024 | -$28.96 | +14.8% |
| 2023 | -$34.01 | -9.2% |
| 2022 | -$31.15 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.37 | +97.4% | +72.2% |
| June 30, 2025 | -$1.33 | +66.9% | -315.6% |
| March 31, 2025 | -$0.32 | +75.6% | +97.7% |
| September 30, 2024 | -$14.21 | -190.0% | -253.5% |
| June 30, 2024 | -$4.02 | +22.8% | -206.9% |
| March 31, 2024 | -$1.31 | +97.6% | +73.3% |
| September 30, 2023 | -$4.90 | -38.8% | +6.0% |
| June 30, 2023 | -$5.21 | -283.1% | +90.6% |
- Bone Biologics Corp showed an increase of +90.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Bone Biologics Corp’s diluted eps has grown by 91.5% (from $31.15 per share (loss) to $2.65 per share (loss)).
- The most recent figure is from Bone Biologics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: